Changeflow GovPing Pharma & Drug Safety Universal Peptide/MHC Complexes with Engineered...
Routine Notice Added Final

Universal Peptide/MHC Complexes with Engineered Disulfide

Email

Summary

The USPTO published patent application US20260097105A1 by Nikolaos SGOURAKIS for synthetic major histocompatibility complex (MHC) molecules featuring engineered disulfide linkages connecting heavy and light chains. The invention covers systems, formulations, and methods for generating universal peptide/MHC complexes using structure-guided modeling and design. Application No. 19114130 was filed September 28, 2023, with CPC classifications including A61K 39/001188, A61K 39/385, C07K 14/4748, and C07K 14/70539.

What changed

The USPTO published a patent application disclosing engineered synthetic MHC (major histocompatibility complex) molecules with engineered disulfide linkages between heavy and light chains. The invention enables generation of universal peptide/MHC complexes through structure-guided modeling and design. The CPC classifications indicate pharmaceutical and therapeutic applications, including A61P 35/00 (antineoplastic agents) and various A61K and C07K codes.

For biotechnology and pharmaceutical companies engaged in immunotherapy research, cancer therapeutics development, or T-cell receptor engineering, this patent application may signal competitive landscape considerations. The universal peptide/MHC platform with engineered disulfide linkages represents a specialized approach to immune-related therapeutic development.

What to do next

  1. Monitor for patent grant status
  2. Evaluate for potential licensing opportunities

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

SYSTEMS, FORMULATIONS AND METHODS FOR GENERATING UNIVERSAL PEPTIDE/MHC COMPLEXES WITH ENGINEERED DISULFIDE CONNECTING THE HEAVY AND LIGHT CHAINS

Application US20260097105A1 Kind: A1 Apr 09, 2026

Inventors

Nikolaos SGOURAKIS

Abstract

The present invention relates to engineering synthetic major histocompatibility complex (MHC) molecules for generating universal peptide/MHC complexes with engineered disulfide linkage(s) using structure-guided modeling and design and method for making and using the same.

CPC Classifications

A61K 39/001188 A61K 39/001191 A61K 39/385 A61P 35/00 C07K 14/4748 C07K 14/70539 A61K 2039/605 C07K 2319/00

Filing Date

2023-09-28

Application No.

19114130

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260097105A1

Who this affects

Applies to
Pharmaceutical companies Medical device makers
Industry sector
3254.1 Biotechnology
Activity scope
Biotechnology R&D Pharmaceutical development Patent filing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.